Nicolson Fay, Ali Akbar, Kircher Moritz F, Pal Suchetan
Department of Imaging Dana-Farber Cancer Institute & Harvard Medical School Boston MA 02215 USA.
Center for Molecular Imaging and Nanotechnology Memorial Sloan Kettering Cancer Center New York NY 10065 USA.
Adv Sci (Weinh). 2020 Oct 15;7(23):2001669. doi: 10.1002/advs.202001669. eCollection 2020 Dec.
In the last two decades, DNA has attracted significant attention toward the development of materials at the nanoscale for emerging applications due to the unparalleled versatility and programmability of DNA building blocks. DNA-based artificial nanomaterials can be broadly classified into two categories: DNA nanostructures (DNA-NSs) and DNA-functionalized nanoparticles (DNA-NPs). More importantly, their use in nanotheranostics, a field that combines diagnostics with therapy via drug or gene delivery in an all-in-one platform, has been applied extensively in recent years to provide personalized cancer treatments. Conveniently, the ease of attachment of both imaging and therapeutic moieties to DNA-NSs or DNA-NPs enables high biostability, biocompatibility, and drug loading capabilities, and as a consequence, has markedly catalyzed the rapid growth of this field. This review aims to provide an overview of the recent progress of DNA-NSs and DNA-NPs as theranostic agents, the use of DNA-NSs and DNA-NPs as gene and drug delivery platforms, and a perspective on their clinical translation in the realm of oncology.
在过去二十年中,由于DNA构建模块具有无与伦比的多功能性和可编程性,DNA在用于新兴应用的纳米级材料开发方面引起了极大关注。基于DNA的人工纳米材料可大致分为两类:DNA纳米结构(DNA-NSs)和DNA功能化纳米颗粒(DNA-NPs)。更重要的是,它们在纳米诊疗领域的应用近年来得到了广泛应用,该领域通过在一体化平台中通过药物或基因递送将诊断与治疗相结合,以提供个性化癌症治疗。方便的是,成像和治疗部分易于附着于DNA-NSs或DNA-NPs,这使得它们具有高生物稳定性、生物相容性和药物负载能力,因此显著推动了该领域的快速发展。本综述旨在概述DNA-NSs和DNA-NPs作为诊疗剂的最新进展、DNA-NSs和DNA-NPs作为基因和药物递送平台的应用,以及对它们在肿瘤学领域临床转化的展望。